BioVenture VoiCes with Chris Garabedian Episode 14: Aditum Bio's Joe Jimenez
Mar 10, 2025
Joe Jimenez, former Novartis CEO and now co-founder of Aditum Bio focused on translational medicine. He traces his path from consumer brands to pharma leadership. He outlines Aditum’s clinic-directed, shared-services model for IND-to-Phase II programs. He explains the firm’s three investment criteria and why they favor predictable biology over early preclinical oncology.
AI Snips
Chapters
Transcript
Episode notes
From Clorox To Pharma Through Board Service
- Joe Jimenez moved from consumer packaged goods into pharma after serving on AstraZeneca's board and falling in love with medicines that change lives.
- He used a 6–8am tutor routine to learn drug mechanisms and pipeline details before running Novartis pharma division.
Pharma Runs Like Consumer Business Except R&D
- Running large pharma is ~80% like consumer packaged goods: procurement, manufacturing, HR and finance matter similarly.
- The major difference is R&D complexity, which demands scientific depth and different timelines.
Three Way Deal That Reshaped Novartis
- To focus Novartis, Jimenez ran ~10 simultaneous M&A talks and engineered a three-way swap with GSK and Lilly to reshape the portfolio.
- He coordinated secret multi-floor negotiations and announced the reshuffle in a single day.